Golf Course Management

MAY 2019

Golf Course Management magazine is dedicated to advancing the golf course superintendent profession and helping GCSAA members achieve career success.

Issue link: http://gcmdigital.gcsaa.org/i/1108924

Contents of this Issue

Navigation

Page 61 of 141

58 GOLF COURSE MANAGEMENT 05.19 AT THE TURN (health) Mike Wallace, CGCS Trials and tribulations Participation in clinical drug trial proves enlightening and triggers reflection from a longtime Connecticut superintendent. Did you ever wonder how a drug for human use makes it to market with all of the different side effects that are listed? Frequently, advertisements mention that a certain product will help with a particular condi - tion, but a certain set of unintended consequences might result. Where and how do they come up with that list? A bit of history is in order here. I was 60 when I was diagnosed with a non-Hodgkin lym - phoma called Waldenstrom macroglobulinemia (WM) in 2010. According to the American Cancer Society: WM cells make large amounts of a certain type of antibody (immunoglobulin M, or IgM), which is known as a macroglobulin. Each antibody (protein) made by the WM cells is the same, so it is called a monoclonal protein, or just an M protein. e buildup of this M protein in the body can lead to many of the symptoms of WM, including excess bleeding, problems with vision, and nervous system problems. ese proteins affect the nerves within your extremities, causing neuropathy, which can be accompanied by severe tingling and discomfort. Neuropathy can then progress to a lack of feel - ing within the extremities. WM is considered an orphan disease, or one that affects fewer than 200,000 nationwide. In the United States, the number of folks who come down with WM are somewhere in the neigh - Waldenstrom macroglobulinemia is considered an orphan disease, or one that affects fewer than 200,000 nationwide A clinical trial is a crucial process in bringing a drug to market, as 2002 GCSAA President Mike Wallace, CGCS, learned when he took part in one to test a drug to treat his rare form of lymphoma. Illustration by Olivier Le Moal/Shutterstock

Articles in this issue

Archives of this issue

view archives of Golf Course Management - MAY 2019